Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Retained Earnings (2016 - 2025)

United Therapeutics (UTHR) has disclosed Retained Earnings for 17 consecutive years, with $8.6 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 18.48% to $8.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 billion through Dec 2025, up 18.48% year-over-year, with the annual reading at $8.6 billion for FY2025, 18.48% up from the prior year.
  • Retained Earnings hit $8.6 billion in Q4 2025 for United Therapeutics, up from $100000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $8.6 billion in Q4 2025 to a low of -$65.5 million in Q2 2022.
  • Historically, Retained Earnings has averaged $4.0 billion across 5 years, with a median of $4.4 billion in 2021.
  • Biggest five-year swings in Retained Earnings: skyrocketed 192485.71% in 2021 and later crashed 101.62% in 2022.
  • Year by year, Retained Earnings stood at $4.3 billion in 2021, then grew by 16.86% to $5.0 billion in 2022, then grew by 19.53% to $6.0 billion in 2023, then increased by 19.83% to $7.2 billion in 2024, then rose by 18.48% to $8.6 billion in 2025.
  • Business Quant data shows Retained Earnings for UTHR at $8.6 billion in Q4 2025, $100000.0 in Q3 2025, and $7.9 billion in Q2 2025.